Tvardi Therapeutics is a clinical-stage biotechnology company founded in 2017 and based in Houston, Texas. The company is dedicated to developing breakthrough medicines targeting diverse cancers, chronic inflammatory diseases, and fibrotic diseases. Tvardi's innovative approach focuses on creating a new class of therapies, including their novel STAT3 inhibitor, TTI-101, which is currently undergoing clinical trials.
Tvardi Therapeutics has made significant strides in the biotech industry, including presenting their Phase 1 clinical trial results for liver cancer at the ASCO Gastrointestinal Cancers Symposium. The company has attracted notable leadership, with Sujal Shah appointed as Chairman and Shaheen Wirk joining the Board of Directors. Tvardi continues to participate in prominent industry conferences, such as the Cowen 44th Annual Health Care Conference, showcasing their commitment to advancing medical research and treatment options.
